Yelena Y Janjigian

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4960905/publications.pdf

Version: 2024-02-01

118	16,071	44069 48	20358 116
papers	citations	h-index	g-index

122	122	122	22430
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics, 2019, 51, 202-206.	21.4	2,702
2	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine, 2017, 23, 703-713.	30.7	2,473
3	OncoKB: A Precision Oncology Knowledge Base. JCO Precision Oncology, 2017, 2017, 1-16.	3.0	1,266
4	First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet, The, 2021, 398, 27-40.	13.7	1,237
5	HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR-Mutant Lung Cancers That Lack the Second-Site EGFRT790M Mutation. Cancer Discovery, 2012, 2, 922-933.	9.4	613
6	CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. Journal of Clinical Oncology, 2018, 36, 2836-2844.	1.6	459
7	Gastric adenocarcinoma. Nature Reviews Disease Primers, 2017, 3, 17036.	30.5	409
8	Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies. Clinical Cancer Research, 2019, 25, 2116-2126.	7.0	390
9	Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitorâ€“Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations. Cancer Discovery, 2014, 4, 1036-1045.	9.4	348
10	The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature, 2021, 600, 727-730.	27.8	335
11	Molecular Classification of Gastric Cancer: A New Paradigm. Clinical Cancer Research, 2011, 17, 2693-2701.	7.0	287
12	Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. Cancer Discovery, 2018, 8, 49-58.	9.4	275
13	First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Lancet Oncology, The, 2020, 21, 821-831.	10.7	243
14	An Emerging Entity: Pancreatic Adenocarcinoma Associated with a Known BRCA Mutation: Clinical Descriptors, Treatment Implications, and Future Directions. Oncologist, 2011, 16, 1397-1402.	3.7	227
15	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell, 2022, 185, 563-575.e11.	28.9	223
16	Chemotherapy and COVID-19 Outcomes in Patients With Cancer. Journal of Clinical Oncology, 2020, 38, 3538-3546.	1.6	195
17	Distinct Clinical Course of EGFR -Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib. Journal of Thoracic Oncology, 2012, 7, 1815-1822.	1.1	160
18	CD44 Expression Denotes a Subpopulation of Gastric Cancer Cells in Which Hedgehog Signaling Promotes Chemotherapy Resistance. Clinical Cancer Research, 2014, 20, 3974-3988.	7.0	159

#	Article	IF	Citations
19	Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature, 2022, 603, 942-948.	27.8	156
20	Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium. Journal of Clinical Oncology, 2015, 33, 3874-3879.	1.6	155
21	Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions. Expert Opinion on Investigational Drugs, 2014, 23, 611-628.	4.1	146
22	MET Expression and Amplification in Patients with Localized Gastric Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1021-1027.	2.5	141
23	Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm. Nature Reviews Clinical Oncology, 2021, 18, 473-487.	27.6	139
24	Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition. Cancer Discovery, 2018, 8, 1540-1547.	9.4	138
25	Clinical impact of tumour biology in the management of gastroesophageal cancer. Nature Reviews Clinical Oncology, 2016, 13, 348-360.	27.6	132
26	Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations. Journal of Thoracic Oncology, 2011, 6, 569-575.	1.1	124
27	First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. Future Oncology, 2021, 17, 491-501.	2.4	117
28	Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib. Clinical Cancer Research, 2011, 17, 2521-2527.	7.0	116
29	EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer. Cancer Discovery, 2019, 9, 199-209.	9.4	115
30	Packâ€years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer. Cancer, 2010, 116, 670-675.	4.1	111
31	Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. Journal of Neuro-Oncology, 2010, 100, 443-447.	2.9	100
32	Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status. Journal of Molecular Diagnostics, 2017, 19, 244-254.	2.8	96
33	Pharmacokinetics, Biodistribution, and Radiation Dosimetry for ⁸⁹Zr-Trastuzumab in Patients with Esophagogastric Cancer. Journal of Nuclear Medicine, 2018, 59, 161-166.	5.0	96
34	Monitoring Afatinib Treatment in HER2-Positive Gastric Cancer with 18F-FDG and 89Zr-Trastuzumab PET. Journal of Nuclear Medicine, 2013, 54, 936-943.	5.0	85
35	Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy. Nature Communications, 2018, 9, 5137.	12.8	78
36	Distinguishing Benign and Life-Threatening Pneumatosis Intestinalis in Patients With Cancer by CT Imaging Features. American Journal of Roentgenology, 2013, 200, 1042-1047.	2.2	75

#	Article	IF	Citations
37	A Randomized Controlled Trial of a Cardiopulmonary Resuscitation Video in Advance Care Planning for Progressive Pancreas and Hepatobiliary Cancer Patients. Journal of Palliative Medicine, 2013, 16, 623-631.	1.1	75
38	Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study.. Journal of Clinical Oncology, 2021, 39, 4013-4013.	1.6	75
39	Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer. Clinical Cancer Research, 2019, 25, 6160-6169.	7.0	73
40	Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody. OncoImmunology, 2017, 6, e1267891.	4.6	66
41	Morbidity after Total Gastrectomy: Analysis of 238 Patients. Journal of the American College of Surgeons, 2015, 220, 863-871e2.	0.5	65
42	Safety and feasibility of esophagectomy following combined immunotherapy and chemoradiotherapy for esophageal cancer. Journal of Thoracic and Cardiovascular Surgery, 2021, 161, 836-843.e1.	0.8	62
43	Human Epidermal Growth Factor Receptor 2 Testing in Gastroesophageal Cancer: Correlation Between Immunohistochemistry and Fluorescence In Situ Hybridization. Archives of Pathology and Laboratory Medicine, 2011, 135, 1460-1465.	2.5	61
44	PKLR promotes colorectal cancer liver colonization through induction of glutathione synthesis. Journal of Clinical Investigation, 2016, 126, 681-694.	8.2	60
45	PCK1 and DHODH drive colorectal cancer liver metastatic colonization and hypoxic growth by promoting nucleotide synthesis. ELife, 2019, 8, .	6.0	59
46	Randomized Phase II Study of PET Responseâ€“Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial. Journal of Clinical Oncology, 2021, 39, 2803-2815.	1.6	58
47	Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib. Clinical Cancer Research, 2011, 17, 6322-6328.	7.0	57
48	Total Gastrectomy for Hereditary Diffuse Gastric Cancer at a Single Center. Annals of Surgery, 2017, 266, 1006-1012.	4.2	56
49	Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab Â± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer. Clinical Cancer Research, 2021, 27, 3926-3935.	7.0	55
50	A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2010, 65, 833-838.	2.3	52
51	OncoTree: A Cancer Classification System for Precision Oncology. JCO Clinical Cancer Informatics, 2021, 5, 221-230.	2.1	51
52	The genomics and therapeutics of HER2-positive gastric cancerâ€”from trastuzumab and beyond. Journal of Gastrointestinal Oncology, 2016, 7, 750-762.	1.4	45
53	YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E6030-E6038.	7.1	44
54	Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 2710-2721.e3.	0.8	41

#	Article	IF	Citations
55	Paradigms for Precision Medicine in Epichaperome Cancer Therapy. Cancer Cell, 2019, 36, 559-573.e7.	16.8	40
56	MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer. Future Oncology, 2022, 18, 2465-2473.	2.4	40
57	Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer. PLoS ONE, 2015, 10, e0134731.	2.5	38
58	Indications for Total Gastrectomy in CDH1 Mutation Carriers and Outcomes of Risk-Reducing Minimally Invasive and Open Gastrectomies. JAMA Surgery, 2020, 155, 1050.	4.3	34
59	⁸⁹Zr-DFO-AMG102 Immuno-PET to Determine Local Hepatocyte Growth Factor Protein Levels in Tumors for Enhanced Patient Selection. Journal of Nuclear Medicine, 2017, 58, 1386-1394.	5.0	33
60	Molecular Stressors Engender Protein Connectivity Dysfunction through Aberrant N-Glycosylation of a Chaperone. Cell Reports, 2020, 31, 107840.	6.4	32
61	Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma. Cancer, 2016, 122, 2083-2090.	4.1	30
62	Prognostic Significance of Targetable Angiogenic and Growth Factors in Patients Undergoing Resection for Gastric and Gastroesophageal Junction Cancers. Annals of Surgical Oncology, 2014, 21, 1130-1137.	1.5	29
63	Temporal Modulation of HER2 Membrane Availability Increases Pertuzumab Uptake and Pretargeted Molecular Imaging of Gastric Tumors. Journal of Nuclear Medicine, 2019, 60, 1569-1578.	5.0	27
64	Neutrophil to Lymphocyte Ratio as Predictor of Treatment Response in Esophageal Squamous Cell Cancer. Annals of Thoracic Surgery, 2018, 106, 864-871.	1.3	26
65	Esophageal Reinforcement with an Extracellular Scaffold During Total Gastrectomy for Gastric Cancer. Annals of Surgical Oncology, 2015, 22, 1252-1257.	1.5	25
66	It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal Adenocarcinoma. Journal of Clinical Oncology, 2017, 35, 475-477.	1.6	25
67	Genomic Dysregulation in gastric tumors. Journal of Surgical Oncology, 2013, 107, 237-242.	1.7	24
68	Risk factors for recurrence in T1â€2N0 gastric cancer in the United States and China. Journal of Surgical Oncology, 2016, 113, 745-749.	1.7	22
69	Incidence and Risk Factors for Isolated Esophageal Cancer Recurrence to the Brain. Annals of Thoracic Surgery, 2020, 109, 329-336.	1.3	20
70	Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer. Annals of Surgical Oncology, 2018, 25, 2027-2033.	1.5	19
71	Current and Future Aspects of Immunotherapy for Esophageal and Gastric Malignancies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 237-247.	3.8	18
72	Lapatinib in Gastric Cancer: What Is the LOGiCal Next Step?. Journal of Clinical Oncology, 2016, 34, 401-403.	1.6	17

#	Article	IF	Citations
73	Comparison of Long- and Short-term Outcomes in 845 Open and Minimally Invasive Gastrectomies for Gastric Cancer in the United States. Annals of Surgical Oncology, 2021, 28, 3532-3544.	1.5	17
74	Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. Lung Cancer, 2017, 113, 51-58.	2.0	16
75	Eradicating micrometastases with immune checkpoint blockade: Strike while the iron is hot. Cancer Cell, 2021, 39, 738-742.	16.8	16
76	Prognostic significance of PET assessment of metabolic response to therapy in oesophageal squamous cell carcinoma. British Journal of Cancer, 2015, 113, 1658-1665.	6.4	15
77	Positron-Emission Tomography Scanâ€"Directed Chemoradiation for Esophageal Squamous Cell Carcinoma: No Benefit for a Change in Chemotherapy in Positron-Emission Tomography Nonresponders. Journal of Thoracic Oncology, 2019, 14, 540-546.	1.1	15
78	Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer. JAMA Network Open, 2021, 4, e2114753.	5.9	15
79	Talking to patients about biosimilars. Future Oncology, 2018, 14, 2403-2414.	2.4	14
80	Outcomes of Neoadjuvant Chemotherapy for Clinical Stages 2 and 3 Gastric Cancer Patients: Analysis of Timing and Site of Recurrence. Annals of Surgical Oncology, 2021, 28, 4829-4838.	1.5	14
81	Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report. Case Reports in Oncology, 2021, 14, 430-438.	0.7	14
82	Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotypeâ€"Phenotype Featuresâ€"An Entity With an Increasing Incidence?. Clinical Colorectal Cancer, 2018, 17, e315-e321.	2.3	13
83	Unique Considerations for Females Undergoing Esophagectomy. Annals of Surgery, 2020, 272, 113-117.	4.2	13
84	A More Extensive Lymphadenectomy Enhances Survival After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Adenocarcinoma. Annals of Surgery, 2022, 276, 312-317.	4.2	13
85	Use of positron emission tomography scan response to guide treatment change for locally advanced gastric cancer: the Memorial Sloan Kettering Cancer Center experience. Journal of Gastrointestinal Oncology, 2016, 7, 506-514.	1.4	12
86	Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer. Gastric Cancer, 2019, 22, 355-362.	5.3	11
87	Efficacy of Combined VEGFR1-3, PDGFÎ±/Î², and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer. Clinical Cancer Research, 2019, 25, 3811-3817.	7.0	10
88	Regorafenib in Combination with Firstâ€Line Chemotherapy for Metastatic Esophagogastric Cancer. Oncologist, 2020, 25, e68-e74.	3.7	10
89	Caveolin-1 temporal modulation enhances antibody drug efficacy in heterogeneous gastric cancer. Nature Communications, 2022, 13, 2526.	12.8	10
90	Post-Treatment/Pre-operative PET Response Is Not an Independent Predictor of Outcomes for Patients With Gastric and GEJ Adenocarcinoma. Annals of Surgery, 2018, 267, 898-904.	4.2	9

#	Article	IF	Citations
91	Checkpoint blockade in esophagogastric cancer. Journal of Surgical Oncology, 2018, 118, 77-85.	1.7	9
92	Oligometastases After Curative Esophagectomy Are Not One Size Fits All. Annals of Thoracic Surgery, 2021, 112, 1775-1781.	1.3	9
93	Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptorâ€“Amplified Gastroesophageal Cancer: Retrospective Global Experience. Journal of Clinical Oncology, 2022, 40, 2458-2467.	1.6	9
94	Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways. Clinical Cancer Research, 2021, 27, 3491-3498.	7.0	8
95	Induction FOLFOX and PET-Directed Chemoradiation for Locally Advanced Esophageal Adenocarcinoma. Annals of Surgery, 2023, 277, e538-e544.	4.2	7
96	Molecularly targeted therapies in advanced gastric cancer. Minerva Gastroenterologica E Dietologica, 2011, 57, 75-88.	2.2	7
97	Phase II Trial of Cetuximab Plus Cisplatin and Irinotecan in Patients With Cisplatin and Irinotecan-refractory Metastatic Esophagogastric Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 126-130.	1.3	6
98	Phase II study of bevacizumab and preoperative chemoradiation for esophageal adenocarcinoma. Journal of Gastrointestinal Oncology, 2016, 7, 828-837.	1.4	6
99	Targeting EGFR in Esophagogastric Cancer. Frontiers in Oncology, 2020, 10, 553876.	2.8	6
100	Survival Following Trimodality Therapy in Patients With Locally Advanced Esophagogastric Adenocarcinoma: Does Only a Complete Pathologic Response Matter?. Annals of Surgery, 2020, , .	4.2	5
101	Defining and Targeting Esophagogastric Cancer Genomic Subsets With Patient-Derived Xenografts. JCO Precision Oncology, 2022, 6, e2100242.	3.0	5
102	Application of positron emission tomography imaging to personalize esophagogastric cancer care. Cancer, 2019, 125, 1214-1217.	4.1	4
103	Postoperative ctDNA monitoring: a canary in a coalmine. Annals of Oncology, 2021, 32, 431-433.	1.2	4
104	Current advances in targeted therapies for metastatic gastric cancer: improving patient care. Future Oncology, 2016, 12, 839-854.	2.4	3
105	Abstract CT228: A phase II study of afatinib (A) in patients (pts) with metastatic human epidermal growth factor receptor (HER2)-positive trastuzumab (T) refractory esophagogastric (EG) cancer. Cancer Research, 2014, 74, CT228-CT228.	0.9	3
106	ATM Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications. Journal of the National Cancer Institute, 2022, 114, 761-770.	6.3	3
107	Comment on â€œMicrosatellite Instability as a Predictive Biomarker for Adjuvant Chemotherapy in Gastric Cancerâ€. Annals of Surgery, 2019, 270, e39-e40.	4.2	2
108	A nutritional management algorithm in older patients with locally advanced esophageal cancer. Journal of Geriatric Oncology, 2021, , .	1.0	2

#	Article	IF	Citations
109	Advances in Oncology in US and Japan: Focusing on Cancer and Infectious Diseases. World Journal of Oncology, 2021, 12, 183-194.	1.5	2
110	Do molecular diagnostics add to clinical characteristics in selecting patients for gefitinib treatment?. Nature Clinical Practice Oncology, 2008, 5, 10-11.	4.3	1
111	Current Progress in Human Epidermal Growth Factor Receptor 2 Targeted Therapies inÂEsophagogastric Cancer. Surgical Oncology Clinics of North America, 2017, 26, 313-324.	1.5	1
112	A case of advanced gastric cancer. Gastrointestinal Cancer Research: GCR, 2012, 5, 59-63.	0.7	1
113	Phase I/Ib study of crenolanib with ramucirumab and paclitaxel as second-line therapy for advanced esophagogastric adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2022, 89, 255-265.	2.3	1
114	Top advances in esophageal/gastroesophageal junction cancers in 2021. Cancer, 2022, 128, 1894-1899.	4.1	1
115	Hepatoid esophagogastric adenocarcinoma and tumoral heterogeneity: a case report. Journal of Gastrointestinal Oncology, 2021, 12, 3123-3132.	1.4	1
116	Association of Obesity with Worse Operative and Oncologic Outcomes for Patients Undergoing Gastric Cancer Resection. Annals of Surgical Oncology, 2021, 28, 7040-7050.	1.5	0
117	Role of HER2 in Gastric Cancers. , 2015, , 77-89.		0
118	Stomach: The Standard of Care Â± HER2. , 2021, , 75-88.		0